Clinical Trials Browser

Phase EARLY_PHASE1 × tafasitamab × 90 days × Clear all

NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase EARLY_PHASE1 Active not recruiting

Lymphoma, B-Cell